MUTYH and breast carcinoma: To address the possibility that the above-described phenomena were a peculiarity of the A2780 ovarian cell line or of the siRNA treatments, we repeated the OGG1- and MYH knock-downs (Supplementary Figure S4B) and NAC treatment with the human, BRCA1-mutated breast cancer cell line SUM149PT.